November 27, 2008
FDA intends to have an Advisory Committee meeting for Multaq® (dronedarone) on March 18, 2009
Dronedarone (Multaq®) is an investigational treatment and the only Anti-Arrhythmic Drug (AAD) to have shown a significant reduction in morbidity and mortality in AF/AFL patients with a favourable safety profile as evidenced by a low incidence of pro-arrhythmia (including torsades de pointes) and extra-cardiac organ toxicity. Dronedarone, discovered and developed by sanofi-aventis, has been studied in a clinical development program including more than 6,200 patients. The landmark ATHENA trial is the only double-blind, anti-arrhythmic, morbidity-mortality study in patients with AF and enrolled a total of 4,628 patients.
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Our shares are listed in Paris and in New York. The sanofi-aventis IR center provides financial and strategic information about the company for investors, individual shareholders and the whole finance community.
November 26, 2008
Sanofi-aventis Europe’s Recommended Offer for Zentiva To remain open until February 20, 2009
November 19, 2008
Sanofi-aventis Announces the Settlement of Nasacort® AQ U.S. Patent Litigation and Certain Allegra®/Allegra® D-12 U.S. Patent Litigations
November 12, 2008
Russia chooses inactivated Polio vaccine from Sanofi Pasteur for primary immunization of all infants
November 10, 2008
Sanofi Pasteur First International Vaccine Company to Enter Japan with Pediatric vaccine
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it is the first international vaccine company to enter the Japanese pediatric vaccine market with ActHIB® vaccine (Haemophilus influenzae type b conjugate vaccine). Sanofi Pasteur’s ActHIB® vaccine is marketed in Japan by Daiichi-Sankyo Co., Ltd., and will be available starting December 19, 2008. The World Health Organization estimates that Hib is responsible for three million serious illnesses and an estimated 400 000 deaths per year worldwide, mainly caused by meningitis and pneumonia. Almost all victims are children under the age of five, those between four and 18 months of age being especially vulnerable. Every year in Japan, about 500 children are affected by this devastating disease, of whom approximately 25 die and 100 suffer from serious sequelæ.
November 5, 2008
Sanofi-aventis to discontinue all clinical trials with rimonabant
October 31, 2008
Third-quarter 2008 results
Net sales: €6,853m, up 5.5% on a comparable basis (down 2.4% on a reported basis)
- Quarterly growth ahead of the pharmaceutical industry
- Good performance from the Top 15 (up 7.3%), especially Lantus® (up 29.1%)
- Leading supplier of influenza vaccines in the USA, and launch of Pentacel®
- 11.5% sales growth in the United States
- Operating income – current1 up 1.2%, or 14.0% excluding the effect of exchange rates
- An improvement of 0.9-point in the ratio of selling and general expenses to net sales, to 24.1%
- Adjusted net income excluding selected items: €1,923m (up 2.1%), and EPS €1.47
up 5.0%)
October 29, 2008
FDA Approves Rapid-Acting Insulin Apidra® for Treatment of Children with Diabetes
October 26, 2008
High-dose influenza vaccine shows increased immune response among adults 65 years of age and older
October 23, 2008
Sanofi-aventis and Medicines for Malaria Venture Enter Into Collaboration to Fight Malaria
October 22, 2008
Sanofi-aventis is complying with the EMEA’s recommendation to temporarily suspend the marketing authorisation of Acomplia® in obese and overweight patients
October 21, 2008
Sanofi-aventis expands its R&D presence in China
October 14, 2008
Sanofi-aventis enters into Collaboration with TB Alliance to Fight Tuberculosis
September 25, 2008
Sanofi Pasteur completes the acquisition of Acambis
Sanofi Pasteur announced today that Sanofi Pasteur Holding has successfully completed the acquisition of Acambis plc for £ 285 million. Acambis becomes today a wholly-owned subsidiary of Sanofi Pasteur Holding, the parent company of Sanofi Pasteur, the vaccines division of the sanofi-aventis Group Acambis is a vaccine company developing novel vaccines that address significant unmet medical needs or substantially improve standards of care. The integration of Acambis’ activities strengthens Sanofi Pasteur’s vaccine pipeline of vaccines in development to better answer global health needs.
September 23, 2008
FDA approves Nasacort AQ® nasal spray for children aged 2-5 years old
Sanofi-aventis announced the U.S. Food and Drug Administration (FDA) has approved Nasacort AQ Nasal Spray (triamcinolone acetonide) for children aged 2 - 5 years old for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis. The FDA based its approval on the results of a multicenter, randomized, double-blind, placebo-controlled study demonstrating that Nasacort AQ can be used safely and effectively to treat nasal symptoms of year-round allergies in children between two and five years. This is the first and largest placebo- controlled trial designed to specifically investigate both the efficacy and safety of an intranasal corticosteroid vs. placebo in 2-5 years of age group.
September 22, 2008
Sanofi-aventis strengthens its position in the Dow Jones Sustainability World Index
The Group ranks among the 7 toprated pharmaceutical companies in sustainability. The Dow Jones Sustainability World Index (DJSI World) features approximately 10% of the topperforming companies in sustainability, among 2500 worldwide. This index evaluates companies' economic, social, societal and environmental performance. The evaluation focuses on corporate governance, risk management, responsible marketing, working conditions, access to medicines and healthcare, relationships with suppliers and climate change.
September 22, 2008
Sanofi-aventis announces intention to raise offer for Zentiva to CZK 1150 in cash per share
September 10, 2008
Upcoming change of Chief Executive Officer
The Board of Directors, in agreement with Mr Gerard Le Fur, wished to organize a change of the General Management of the Group, and thereby to entrust the realization of this strategy to a person able to implement it in the long term. To this end, the Board has decided that Mr Chris Viehbacher will succeed Mr Gerard Le Fur as Chief Executive Officer (CEO) of the Group, as of December 1st, 2008. Mr Gerard Le Fur will continue to provide his competences to the General Management of the Group in the scientific domain.
September 2, 2008
Acambis’ shareholders approve Sanofi Pasteur Holding’s offer by a large majority
September 1, 2008
Sanofi-aventis acquisition of Symbion Consumer in Australia now completed
Sanofi-aventis announced today the completion of the acquisition of the Australian company Symbion CP Holdings Pty Limited (“Symbion Consumer”)
for A$ 560 million. Symbion Consumer manufactures, markets and distributes nutraceuticals (vitamins & mineral supplements) and over the counter brands throughout Australia and New Zealand. Symbion Consumer has a strong portfolio of premium brands including Natures Own, Cenovis, Bio-organics, Golden Glow and Microgenics. In 2007, Symbion Consumer sales amounted to around A$ 190 million. Sales will be consolidated by sanofi-aventis as from September 1, 2008.
September 1, 2008
“Taxotere® Injection” (docetaxel hydrate) approved in Japan for the treatment of prostate cancer
August 1, 2008
Sanofi Pasteur shipping first doses of influenza vaccine for the 2008-2009 season in the US
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, began shipping influenza vaccine (Fluzone®, Influenza Virus Vaccine) in the United States for the 2008-2009 season. The first 1.3 million doses of influenza vaccine began shipping this week following marketing clearance of the 2008-2009 formulation by the U.S. Food and Drug Administration (FDA) on July 14, 2008. Vaccine shipments to health-care providers and to the Centers for Disease Control and Prevention (CDC) for distribution through the Vaccines for Children Program will continue through the fall and are planned to be completed in October. This year’s influenza vaccine contains three new strains of the influenza virus, A/Brisbane/59/2007 (H1N1)-like virus; A/Brisbane/10/2007 (H3N2)-like virus; B/Florida/4/2006-like virus. The three strains for the new influenza vaccine formulation were confirmed by the FDA's Vaccines and Related Biological Products Advisory Committee in February 2008 and correspond with recommendations made by the World Health Organization in February. Unlike other routinely recommended vaccines whose formulation remains constant over time, influenza vaccine is formulated each year to match the strains predicted to circulate during the upcoming season.
July 31, 2008
Availability on line of the Group’s half-year financial report for 2008
July 31, 2008
Second quarter 2008 results
Net sales: €6,689m, up 5.2% on a comparable basis (down 3.6% on a reported basis)
- 4.1% growth for the Pharmaceuticals business
- Good performance from flagship products
- Resilience from the rest of the portfolio: net sales up 0.8%
- Strong growth in Vaccines (up 17.1% on a comparable basis)
- Double-digit growth in emerging markets
- 11.2% growth in operating income – current1 excluding currency effects
- Ongoing cost control measures, and further improvement in the ratio of selling and general expenses to net sales (26.7% vs. 27.8%)
Adjusted net income excluding selected items: €1,753m, up 0.7% (up 3.9% per share)
July 25, 2008
Recommended Offer by Sanofi Pasteur for Acambis plc
July 24, 2008
European Commission approved APIDRA® for treatment of children & adolescents with diabetes
July 21, 2008
Sanofi-aventis enters into agreement with Primary Health Care to acquire “Symbion Consumer”, its nutraceuticals & OTC division, in Australia
July 18, 2008
Sanofi-aventis announces the termination of development and commercialization agreement for S-1 with Taiho Pharmaceutical
June 23, 2008
U.S. FDA licenses Sanofi Pasteur’s new pediatric combination vaccine, Pentacel®
June 18, 2008
Sanofi-aventis intends to make a Competing Bid of CzK 1,050 in cash per share for Zentiva
June 16, 2008
Sanofi Pasteur to donate 60 million doses of H5N1 vaccine to WHO over 3 years for its influenza vaccine global stockpile
June 10, 2008
Five-year safety study examines the effect of LANTUS® on the progression of retinopathy in people with type 2 diabetes
June 7, 2008
Insulin Glulisine APIDRA® efficacy in the treatment of children and adolescents with type 1 diabetes
May 15, 2008
Landmark ATHENA Study Findings With Multaq® (dronedarone) Show 24% Reduction in Cardiovascular Hospitalisation or Death in Patients With Atrial Fibrillation.
District Court Decision affirmed in U.S. Lovenox® (enoxaparin sodium) patent infringement case
Sanofi-aventis announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the February 8, 2007 decision by the U.S. District Court for the Central District of California in the sanofi-aventis Lovenox® patent infringement suit against Amphastar and Teva. As a result of the Court of Appeals’ ruling, the U.S. Lovenox® patent is deemed to be unenforceable. Sanofi-aventis is considering all its legal options. While several generic manufacturers have requested marketing approval from the FDA for their products alleged to be generic versions of Lovenox®, sanofi-aventis has not learned of any FDA approval of these requests.
April 28, 2008
U.S. Government accepts $192 million of Sanofi Pasteur H5N1 bulk vaccine antigen for pandemic stockpile
April 22, 2008
Malaria: strong partnerships aiming to benefit patients in Africa
April 15, 2008
Sanofi Pasteur invests 100 million Canadian dollars in an R&D facility in Canada to Boost Innovation in Vaccine Research for Global Health
March 13, 2008
U.S. FDA Licenses DAPTACEL® Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series
February 26, 2008
Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America
February 19, 2008
FDA approves XYZAL® (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
February 12, 2008
2007 earnings ahead of guidance - Sharp rise in proposed dividend
Fourth quarter:
-Net sales down 2.2% on a comparable basis (or 6.0% on a reported basis) at €6,911 million
-Growth of 5.7% in pharmaceuticals net sales after excluding the impact of generics of Ambien®
-IR in the United States and Eloxatin® in Europe3
-Growth in earnings despite the negative effects of the euro/dollar exchange rate and of earlier shipments of influenza vaccines than in 2006
2007 full year: €5.28 adjusted EPS with selected items; €5.17 excluding selected items:
-Net sales up 2.8% on a comparable basis (down 1.1% on a reported basis) at €28,052 million
-Growth of 6.4% in Pharmaceuticals net sales after excluding the impact of generics of
-Ambien® IR in the United States and Eloxatin® in Europe3; 14.5% growth in Vaccines net sales
-Lantus®: First insulin brand to exceed €2 billion of sales
-Marked decline in selling and general expenses, with the ratio of selling and general expenses
down 1.4 points at 26.9%
Earnings ahead of full-year guidance4:
-Business development highlights: signature of alliance agreements with Regeneron, Acambis,
-Crucell and Oxford Biomedica, and buyout of rights to several of our products in Japan
-Share repurchase program and dividend
-29.4 million shares repurchased in 2007 for a total of €1.8 billion
- A dividend increase of 18.3% to €2.07 per share proposed to the Shareholders’ Annual General Meeting
February 12, 2008
Sanofi-aventis enters into Antibody Agreements with Dyax for the fully human monoclonal antibody DX-2240 and "Phage Display Technology"
January 28, 2008
Clexane®/Lovenox® approved in Japan
